Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Optimum bowel cleansing before colonoscopy

This month's issue of the American Journal of Gastroenterology examines a dual-action, low-volume bowel cleanser administered the day before colonoscopy.

News image

Optimal bowel preparation is vital for the efficacy and safety of colonoscopy.

The inconvenience, discomfort, required consumption of large volumes of product, and potential adverse effects associated with some bowel preparations deter patients from colonoscopy, and may provide inadequate cleansing.

A dual-action, non-phosphate, natural orange-flavored, low-volume preparation containing sodium picosulfate and magnesium citrate (P/MC) is being reviewed for bowel cleansing.

Dr Philip Katz and colleagues from Pennsylvania, USA reported that this was a phase 3, randomized, multicenter, assessor-blinded, prespecified non-inferiority, head-to-head study.

The team investigated the efficacy, safety, and tolerability of day-before administration of picosulfate and magnesium citrate vs 2L polyethylene glycol solution, and 2 5-mg bisacodyl tablets in adult patients preparing for colonoscopy.

The primary objective was to demonstrate the non-inferiority of picosulfate and magnesium citrate to 2L PEG-3350 and bisacodyl tablets in overall colon cleansing using a modified Aronchick scale.

The doctors also evaluated the efficacy in the ascending, mid, and recto-sigmoid segments of colon using a modified Ottawa scale.

Patient acceptability and tolerability of the bowel preparations were assessed via a standard questionnaire.

Adverse events related to the bowel preparation were reported by 1% of patients
American Journal of Gastroenterology

The research team assessed safety based on the monitoring of adverse events and meaningful findings on clinical evaluations including physical examinations, vital sign measurements, and electrocardiograms.

A total of 603 patients were randomized to receive either picosulfate and magnesium citrate or 2L PEG-3350 and bisacodyl tablets.

The team of doctors noted that based on the Aronchick scale, successful overall cleansing was similar in patients receiving picosulfate and magnesium citrate.

Patients receiving 2L PEG-3350 and bisacodyl tablets picosulfate and magnesium citrate demonstrated non-inferiority to 2L PEG-3350 and bisacodyl tablets in overall cleansing of the colon, as measured by the Aronchick scale.

Similarly, the efficacy of picosulfate and magnesium citrate , as measured by the Ottawa scale, was non-inferior to 2L PEG-3350 and bisacodyl tablets in cleansing the ascending, mid, and recto-sigmoid segments of the colon.

The researchers noted that patient-reported acceptability and tolerability for each item examined on the questionnaire was significantly greater for picosulfate and magnesium citrate compared with 2L PEG-3350 and bisacodyl tablets.

Treatment-emergent adverse events related to the bowel preparation reported by 1% of patients receiving picosulfate and magnesium citrate or 2L PEG-3350 and bisacodyl tablets were nausea, vomiting, and headache.

No clinically meaningful changes were noted in either treatment arm in data collected from physical examinations, vital sign measurements, and ECGs.

Dr Katz's team commented "When administered as a day-before dose, the bowel cleansing effects of picosulfate and magnesium citrate were non-inferior compared with 2L PEG-3350 and bisacodyl tablets using the clinician-rated Aronchick and Ottawa scales."

"Treatment acceptability was significantly more favorable in patients receiving picosulfate and magnesium citrate  than in patients receiving 2L PEG-3350 and bisacodyl tablets."

Am J Gastroenterol 2013; 108: 401409
20 March 2013

Go to top of page Email this page Email this page to a colleague

 28 January 2015

Advanced search
 28 January 2015 
Metabolic syndrome in celiac disease
 28 January 2015 
Remission in Crohn's disease
 28 January 2015 
Surgery and quality of life in rectal cancer
 27 January 2015 
Outcomes for liver transplantation
 27 January 2015 
Psychological distress and fecal composition in IBS
 27 January 2015 
Risk of upper GI cancers in GERD
 26 January 2015 
Breath analysis for IBD
 26 January 2015 
Fecal microbiota transplantation
 26 January 2015 
Antidepressants and GERD
 23 January 2015 
Liver transplant outcomes
 23 January 2015 
Breath analysis in IBD
 23 January 2015 
Fecal microbiota transplantation
 22 January 2015 
NASH and lipid improvements
 22 January 2015 
NAFLD and NASH with psoriasis
 22 January 2015 
Predicting outcomes in HCV-related advanced liver disease
 21 January 2015 
Colon capsule versus CT colonography
 21 January 2015 
Barrett's esophagus screening in the community
 21 January 2015 
Portal vein obstruction
 20 January 2015 
Modulating mucosal damage in Crohn's
 20 January 2015 
Novel techniques for Barrett's screening
 20 January 2015 
Food intolerance
 19 January 2015 
Treatment of fecal incontinence
 19 January 2015 
Hepatic cyst infection
 19 January 2015 
Risk of IBS among relatives
 16 January 2015 
Colorectal cancer screening uptake
 16 January 2015 
NAFLD and NASH in patients with psoriasis
 16 January 2015 
Fecal incontinence
 15 January 2015 
Coffee intake and liver disease
 15 January 2015 
NAFLD in primary care practice
 15 January 2015 
Management of univestigated dyspepsia
 14 January 2015 
Missed colorectal cancers after colonoscopy with polypectomy
 14 January 2015 
Inflixmab response in Crohn's
 14 January 2015 
Statins and liver injury in chronic liver disease
 13 January 2015 
Cytomegalovirus in IBD
 13 January 2015 
Helicobacter-negative gastritis
 13 January 2015 
Hep B vaccine in IBD
 12 January 2015 
Survival in Hep B virus-related hepatocellular carcinoma
 12 January 2015 
Relapse of Crohn's disease after surgery
 12 January 2015 
Late liver metastases of colorectal cancer
 09 January 2015 
Fecal microbiota transplantation for refractory Crohn's
 09 January 2015 
Hypercoagulability after liver resection
 09 January 2015 
Naps and gastroesophageal reflux vs nocturnal sleep
 08 January 2015 
Post-infectious functional dyspepsia
 08 January 2015 
Diagnosis of liver iron overload
 08 January 2015 
Digestive tract damage in Crohn's disease
 07 January 2015 
Early-onset colorectal cancer
 07 January 2015 
SSRIs for noncardiac chest pain
 07 January 2015 
SSRIs and upper GI bleeds
 06 January 2015 
Detection of inflammation in Crohn's
 06 January 2015 
Leptin and early-onset extreme obesity
 06 January 2015 
Goals of IBD treatment
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives
 18 December 2014 
Vitamin D and sustained virologic response in HCV
 18 December 2014 
Factor for treatment in IBS
 18 December 2014 
Assessment of Crohn's disease activity
 17 December 2014 
Remission from hepatic encephalopathy with rifaximin
 17 December 2014 
Colonic adenoma recurrence after endoscopic resection
 17 December 2014 
Non-invasive measures of fatty liver

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us